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Background and objectives: Cardiovascular disease (CVD) and chronic obstructive 
 pulmonary disease (COPD) commonly coexist and share common risk factors. The prevalence 
of COPD in outpatients with a smoking history and CVD in Japan is unknown. The aim of 
this study was to determine the proportion of Japanese patients with a smoking history being 
treated for CVD who have concurrent airflow limitation compatible with COPD. A secondary 
objective was to test whether the usage of lung function tests performed in the clinic influenced 
the diagnosis rate of COPD in the patients identified with airflow limitation.
Methods: In a multicenter observational prospective study conducted at 17 centers across Japan, 
the prevalence of airflow limitation compatible with COPD (defined as forced expiratory volume 
(FEV)
1
/FEV
6
 ,0.73, by handheld spirometry) was investigated in cardiac outpatients $40 years 
old with a smoking history who routinely visited the clinic for their CVD. Each patient completed 
the COPD Assessment Test prior to spirometry testing.
Results: Data were available for 995 patients with a mean age of 66.6±10.0 years, of whom 
95.5% were male. The prevalence of airflow limitation compatible with COPD was 27.0% 
(n=269), and 87.7% of those patients (n=236) did not have a prior diagnosis of COPD. The 
prevalence of previously diagnosed airflow limitation was higher in sites with higher usage of 
lung function testing (14.0%, 15.2% respectively) compared against sites where it is performed 
seldom (11.1%), but was still low.
Conclusion: The prevalence of airflow limitation in this study indicates that a quarter of 
 outpatients with CVD have COPD, almost all of whom are undiagnosed. This suggests that it 
is important to look routinely for COPD in CVD outpatients.
Keywords: COPD, CVD, handheld spirometer, lung function, diagnosis
Introduction
The prevalence of chronic obstructive pulmonary disease (COPD) is expected to 
increase globally.1,2 There is significant underdiagnosis of COPD in Japan, partly 
because spirometry testing is limited3 and symptoms appear progressively, becoming 
obvious only when lung function is already significantly impaired.4 Previous data have 
shown that spirometry screening during medical checkups can identify many patients 
with COPD who are not aware of this disease.5
COPD is associated with increased risk of cardiovascular disease (CVD) and, 
in subjects with CVD, the coexistence of COPD is associated with raised morbidity, 
including a worsening of symptoms and more frequent hospitalizations.6,7,8 In 
addition, cardiovascular deaths are a significant cause of mortality in COPD 
patients.9
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Surveys have been performed to look at the prevalence 
of COPD in patients consulting medical institutions special-
izing in circulatory diseases. In Spain, airflow limitation 
was detected in 19% of patients with CVD.10 In Japan, from 
patients consulting the cardiovascular department of a uni-
versity hospital, the prevalence of airflow limitation ranged 
from 10%–25%, depending on the primary conditions of the 
sampled patients.11,12 However, the possibility of a significant 
risk of the comorbidity of COPD and CVD is not widely 
accepted in Japan.
The combination of COPD with CVD is known to be 
associated with poorer prognosis,7–9 largely attributed to 
increased systemic inflammation.13 Observational data have 
suggested that slowing COPD progression may help to reduce 
cardiovascular morbidity and mortality, which are them-
selves associated with more severe pulmonary  symptoms.14 
Exacerbations of COPD have been demonstrated to increase 
the risk of myocardial infarction and stroke,15 and COPD 
patients with CVD have significantly higher risk of COPD 
exacerbations and increased costs than COPD patients 
without CVD.16 Therefore, there is a good rationale for 
case-finding for COPD, in order to manage the disease as 
early as possible, prevent exacerbations, and reduce the risk 
of cardiovascular events.17
The aim of this study was to determine the proportion of 
Japanese patients with a smoking history being treated for 
cardiovascular disease who have concurrent airflow limita-
tion compatible with COPD. A secondary objective was to 
test whether the usage of respiratory function tests performed 
in the clinic influenced the diagnosis rate of COPD in patients 
identified with airflow limitation.
Methods
study design
This study was a multicenter prospective observational study 
conducted at 17 clinics in Japan; in consecutive outpatients 
with a smoking history who routinely visited the clinic for 
their CVD. All patients gave written consent to participate in 
the study. Patients who were $40 years old and had a smoking 
history of $10 pack-years were enrolled in the study. Patients 
with hypertension were required to have received drug therapy 
for at least 1 year to be included. Any patient who had difficulty 
in performing spirometry on the day of the study visit, due to 
an acute respiratory infection, was required to return when 
the infection had resolved without the use of bronchodilator. 
Patients diagnosed with bronchial asthma were excluded.
Assessments were made at a single visit. Patients were 
asked to complete the COPD Assessment Test (CAT) 
 questionnaire18 and a pulmonary function test, using a 
handheld spirometer: Hi-Checker (Takara Tsusho Co, Ltd, 
Tokyo, Japan) or Vitalograph (Vitalograph Inc., Lenexa, 
KS, USA). Forced expiratory volume in 1 second (FEV
1
), 
and in 6 seconds (FEV
6
) was measured prior to bronchodila-
tor use. A predicted FEV
1
 value was calculated according 
to the formula used by the Lung Physiology Committee of 
the Japanese Respiratory Society.19 Airflow limitation was 
defined as FEV
1
/FEV
6
 ratio ,0.73. The FEV
1
/FEV
6
 ratio can 
be used as a valid alternative for FEV
1
/forced vital capacity 
(FVC) in the diagnosis of airway obstruction.20 Demography 
and details of concurrent diseases and medications were 
collected. Chronic bronchitis was defined as the presence 
of sputum for at least 3 months of the year, for more than 2 
consecutive years.
analysis
The primary analysis set was the per protocol population. 
Study centers were stratified into three subsets based on the 
usage of pulmonary function tests. This was decided at the dis-
cretion of the cardiologists who participated in the study. Data 
analyses were performed for each subset. The subsets were 
classified as centers that performed pulmonary function tests 
often ($10 times/month), less often (2–10 times/month), and 
seldom (,2 times/month). A stratified analysis was performed 
based on demographic and other baseline  characteristics. The 
mean values and 95% confidence intervals were calculated 
for FEV
1
, FEV
6
, and percentage of predicted FEV
1
 and FEV
1
/
FEV
6
 values. Differences between groups were statistically 
analyzed by the chi-squared test. A P-value ,0.05 was con-
sidered statistically significant.
Results
A total of 1,001 subjects were enrolled in the study. The study 
population consisted of 995 subjects for whom spirometry 
data and CAT assessment were available; six patients were 
removed due to a protocol violation or an inappropriate 
spirometry procedure.
The baseline demographics are shown in Table 1. The mean 
age of the study population was 66.6±10.0 years, and the major-
ity of patients were male (95.5%). Hypertension was the most 
common CVD, which was reported in 74.0% of patients – the 
second highest CVD being arrhythmia (20.1%).
The prevalence of airflow limitation in this study was 
27.0% (n=269). Of these, 87.7% (n=236) did not have a 
previous diagnosis of COPD (Table 2). At the discretion of 
the consulting cardiologist centers were grouped by their 
usage of lung function tests. Four sites were classed as “often” 
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(n=184 patients), three sites as “less often” (n=182 patients), 
and ten sites as “seldom” (n=629 patients). The prevalence 
of airflow limitation, split by the usage of lung function test, 
shows that even at sites categorized as ”often”, the level of 
undiagnosed COPD was high. But it was lower than at the 
sites classified as “seldom” (Table 2).
Table 2 The number of patients with airflow limitation and a 
previous diagnosis of COPD
Total subjects in per protocol population 
(n=995)
Airflow limitation  
(prevalence of COPD)  
n=269
Previous diagnosis 
of COPD  
n=33
Total 27.0% 12.3%
Split by age range
40–49 years 5.1% 0%
50–59 years 16.6% 3.8%
60–69 years 21.4% 12.5%
.70 years 39.4% 13.8%
Lung function tests performed*
Often 23.4% 14.0%
less often 25.3% 15.2%
seldom 28.6% 11.1%
Note: *split at the discretion of the consulting cardiologist.
Abbreviation: COPD, chronic obstructive pulmonary disease.
Table 1 Baseline demographics of the per protocol population
n=995
Mean age (sD); years 66.6 (9.96)
Male; n (%) 950 (95.5)
Current smoker; n (%) 273 (27.4)
ex-smoker; n (%) 722 (72.6)
smoking pack-years; mean (sD) 43.1 (26.08)
BMI; mean (sD) 24.64 (3.48)
Diagnosed COPD; n (%) 48 (4.8)
Chronic sputum; n (%) 203 (20.4)
FeV1; mean (sD) 2.29 (0.70)
FeV6; mean (sD) 2.97 (0.79)
CaT score; mean (sD) 6.9 (5.8)
Myocardial infarction; n (%) 158 (15.9)
hypertension; n (%) 736 (74.0)
Chronic heart failure; n (%) 113 (11.4)
angina; n (%) 192 (19.3)
arrhythmia; n (%) 200 (20.1)
stroke; n (%) 48 (4.8)
arteriosclerosis; n (%) 24 (2.4)
Other CVD; n (%) 187 (18.8)
1 CVD; n (%) 576 (57.9)
2 CVD; n (%) 253 (25.4)
3 CVD; n (%) 108 (10.9)
4 CVD or more; n (%) 58 (5.8)
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; COPD, chronic 
obstructive pulmonary disease; sD, standard deviation; CaT, COPD assessment 
test; FeV1, forced expiratory volume in 1 second; FeV6, forced expiratory volume 
in 6 seconds.
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Figure 1 gOlD grading of patients with and without airway limitation.
Abbreviations: al, airway limitation; FeV1, forced expiratory volume in 1 second; 
gOlD, global initiative for chronic Obstructive lung Disease.
The mean percentage of predicted FEV
1
 of the total 
study population was 62.5%±17.8%. Compared against 
the Global initiative for chronic Obstructive Lung Disease 
(GOLD) classification26 (the majority of patients having an 
FEV
1
 between 50%–79%; GOLD Grade 2), 20% of patients 
had lung function less than 50% of predicted FEV
1
. The 
values in this study are prebronchodilator, not postbroncho-
dilator (as in GOLD) (Figure 1).
The demographic characteristics of patients who had 
airflow limitation, or did not, are shown in Table 3. In the 
subjects with airflow limitation, significant differences 
were observed, with lower body mass index, greater age, 
more chronic bronchitic symptoms, and higher CAT score. 
There was no significant difference in the number of patients 
between airflow limitation and no airflow limitation, within 
the CVDs of ischemic heart disease, chronic heart failure, and 
arrhythmias (Table 3). Percentages of patients with airflow 
limitation in each CVD are shown in Table 4.
Discussion
Airflow limitation compatible with COPD was present in 
27.0% of outpatients with CVD and a history of smoking, 
with almost all of them being undiagnosed prior to this 
study. This prevalence estimate is in agreement with previous 
studies, which have reported that the prevalence of COPD 
is in the range 12%–34% amongst patients with coronary 
artery disease.10,21–24 In a study conducted by Soriano et al,10 
the prevalence of airway limitation was 19.2% in subjects 
with CVD. It was not a Japanese study and lacked criteria 
for age and smoking history; the prevalence was lower than 
our study result. In studies conducted by Wada et al11 and 
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entry criteria for smoking.11 In the Yamasaki et al study there 
were no entry criteria for age or smoking.12
In our study, the presence of COPD was shown to increase 
with age, as expected, but undiagnosed airflow limitation was 
also seen in patients as young as 40–49 years. There were 
statistically significant differences observed between patients 
with and without airflow limitation, for parameters including 
age, smoking pack-years, CAT score, chronic bronchitis, 
and body mass index. In patients with chronic bronchitic 
symptoms, 33.5% had airflow limitation, suggesting that 
this history may be a useful predictor of COPD amongst 
patients with CVD. This has also been demonstrated recently 
in another study, which showed that underdiagnosis of COPD 
was particularly a problem in younger men with chronic 
bronchitic symptoms – a phenotype which is not usually 
recognized as COPD in Japan25 because the Japanese COPD 
phenotype tends to be seen as: older, more emphysemic, less 
exacerbations, and less chronic bronchitic. Increased risk of 
COPD was associated with all CVDs; in our study, there was 
no significant difference in the number of patients with or 
without airflow limitation, with the CVDs of ischemic heart 
disease, coronary heart failure, and arrhythmias.
In this study, when patients were categorized using the 
GOLD criteria for airflow limitation,26 the majority (55%) 
were in GOLD Grade 2, but 20% of patients had an FEV
1
 
less than 50% of predicted, showing that even patients with 
severe-to-very-severe airflow limitation had not been previ-
ously diagnosed. Patients with COPD categorized as GOLD 
Grade 1 show an increased risk of mortality, so it is important 
to find and treat these undiagnosed patients.27
The prevalence of patients with airflow limitation was 
spread fairly evenly between the centers (split by the usage 
of lung function testing). As expected, there were a higher 
number of patients with a prior diagnosis of COPD in the 
centers with greater use of spirometry, compared with the 
centers where its use was “seldom”. But even those centers 
classed as having using spirometry “often” had a high number 
of CVD patients with undiagnosed COPD.
Patients with CVD and a smoking history are at increased 
risk of airway limitation, and should benefit from lung func-
tion screening, as they have been reported to be frequently 
asymptomatic.28 The mean CAT score in patients with air-
flow limitation was a little higher (8.3±6.5), compared with 
patients with no airflow limitation (6.4±5.4). The score for 
patients with airflow limitation was lower than for patients 
with diagnosed COPD,18 but it should be appreciated that 
most of the patients in our study had not been diagnosed 
with COPD – presumably, because their symptoms were 
Table 3 Characteristics of patients with and without airflow 
limitation (prevalence of COPD)
Airflow  
limitation  
(n=269)
No airflow  
limitation  
(n=726)
Airway 
limitation 
versus 
no airway 
limitation*
age, mean (sD) 71.0 (8.8) 65.0 (9.8) P,0.001
Males, n (%) 258 (96%) 692 (95%) P=0.689
Current smoker; n (%) 76 (28.3%) 197 (27.1%) P=0.726
ex-smoker; n (%) 193 (71.7%) 529 (72.9%)
Pack-years; mean (sD) 48.6 (26.2) 41.1 (25.8) P,0.001
BMI; mean (sD) 23.3 (3.1) 25.1 (3.4) P,0.001
Diagnosis of COPD; n (%) 33 (12.3%) 15 (2%) P,0.001
Positive chronic  
bronchitis criteria n (%)
68 (25.3%) 135 (18.6%) P=0.020
FeV1; mean (sD) 1.776 (0.64) 2.483 (0.62) P,0.001
FeV6; mean (sD) 2.789 (0.81) 3.034 (0.77) P,0.001
CaT score; mean (sD) 8.3 (6.5) 6.4 (5.4) P,0.001
CV history
Myocardial infarction 41 (15.2%) 117 (16.1%)
hypertension 207 (77.0%) 529 (72.9%)
Chronic heart failure 34 (12.6%) 79 (10.9%)
angina 46 (17.1%) 146 (20.1%)
arrhythmia 59 (21.9%) 141 (19.4%)
stroke 18 (6.7%) 30 (4.1%)
arteriosclerosis 9 (3.3%) 15 (2.1%)
Other CVD 48 (17.8%) 139 (19.1%)
hypertension only 110 (40.9%) 293 (40.4%)
Note: *Chi-squared test.
Abbreviations: CV, cardiovascular; CVD, cardiovascular disease; COPD, chronic 
obstructive pulmonary disease; sD, standard deviation; CaT, COPD assessment 
test; FeV1, forced expiratory volume in 1 second; FeV6, forced expiratory volume 
in 6 seconds.
Table 4 The number of patients with airflow limitation by CV 
history
CV history n Airflow limitation 
n (%)
Myocardial infarction 158 41 (25.9%)
hypertension 736 207 (28.1%)
Chronic heart failure 113 34 (30.1%)
angina 192 46 (24.0%)
arrhythmia 200 59 (29.5%)
stroke 48 18 (37.5%)
arteriosclerosis 24 9 (37.5%)
Other CVD 187 48 (25.7%)
hypertension only 403 110 (27.3%)
Abbreviations: CV, cardiovascular; CVD, cardiovascular disease.
Yamasaki et al12 in Japan, the prevalence of airflow limita-
tion in patients with CVD was also lower (10.9% and 22.6%, 
respectively). These studies were both conducted on single 
sites. In the Wada et al study, there was good collaboration 
between cardiology and respirology. Additionally, although 
this study excluded subjects ,40 years old, there were no 
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inconclusive. Support for this interpretation comes from 
Miravitlles et al,29 who showed that St George’s Respiratory 
Questionnaire scores in people identified as having COPD on 
screening were significantly lower than in those with a prior 
COPD diagnosis, and only a little higher than the normal 
range. CAT scores in CVD patients were similar to those 
seen in Japanese workers with undiagnosed airflow limitation, 
identified in a screening spirometry study.30
There are some limitations of this study. We recruited 
patients older than .40 years old with a smoking history; 
smoking is not prevalent among Japanese women of this age 
group. Further study is needed to confirm the prevalence of 
COPD among nonsmokers.
Conclusion
Airflow limitation compatible with COPD was seen in a 
quarter of outpatients with CVD in our study, with almost all 
of them being undiagnosed. This suggests that it is important 
to look routinely for COPD in CVD patients .40 years old 
with a history of smoking, as the combination of COPD with 
CVD is known to be associated with poorer prognosis.
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